BSE Live
Feb 13, 16:01Prev. Close
1274.55
Open Price
1274.00
Bid Price (Qty.)
1265.10 (2)
Offer Price (Qty.)
1274.10 (3)
NSE Live
Feb 13, 15:57Prev. Close
1274.90
Open Price
1274.00
Bid Price (Qty.)
1268.10 (4)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Dr Reddys Laboratories (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 44.36 | 303.34 | |
| Net CashFlow From Operating Activities | 250.54 | 364.27 | |
| Net Cash Used In Investing Activities | 69.35 | -627.22 | |
| Net Cash Used From Financing Activities | 161.90 | -15.88 | |
| Foreign Exchange Gains / Losses | 1.85 | -1.56 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 483.64 | -280.39 | |
| Cash And Cash Equivalents Begin of Year | 408.08 | 688.47 | |
| Cash And Cash Equivalents End Of Year | 891.72 | 408.08 |
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
22.01.2026
16.01.2026
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz